Quantcast

Latest Adderall Stories

2014-10-20 16:27:42

DUBLIN, October 20, 2014 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Break fee of $1.635bn Now Payable Independent Shire Positioned for Sustainable Growth - In light of the AbbVie Board's decision to...

2014-10-20 04:21:19

DUBLIN, October 20, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling, Interim Chief Financial Officer (CFO), has notified the Board of Directors of his decision to step down from his current role to pursue a new career opportunity as CFO of Severn Trent plc. James will leave Shire at the end of Q1 2015 and the company will commence a search for a new CFO immediately. Flemming Ornskov, Shire's Chief Executive Officer, commented:...

2014-10-13 16:25:01

WEST HOLLYWOOD, Calif., Oct. 13, 2014 /PRNewswire-USNewswire/ -- Records show that Dr. Kuemmerle, a methamphetamine addict, was the most prolific prescriber of Adderall and the second-highest prescriber of narcotics in the state. His reckless prescribing went uninvestigated until a drug dealer Dr. Kuemmerle was selling prescriptions to was arrested by an undercover officer. The police investigation found that Dr. Kuemmerle was writing prescriptions to people he had never met, with...

2014-10-09 04:20:56

PHILADELPHIA, October 9, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it has received further guidance from the U.S. Food and Drug Administration (FDA) on the regulatory path for SHP 465 (triple-bead mixed amphetamine salts MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. On April 25, 2014, in written correspondence, the FDA responded to...

2014-10-07 23:12:05

The Corporate Whistleblower Center is urging pharmaceutical company representatives, managers, or physicians to call them at 866-714-6466, if they have well documented proof a drug company is selling a drug product under false pretenses, or if the company is selling the drug off label. There was a recent announcement about a multi million dollar reward to a whistleblower who stepped forward with this exact type of information. http://CorporateWhistleblowerCenter.Com (PRWEB) October 07,...

2014-09-24 23:02:25

Pharmaceutical Company Agrees to Pay U.S. and State Governments to Settle Off-Label Drug Marketing and False Claims Act Allegations Philadelphia, PA (PRWEB) September 24, 2014 Stephen A. Sheller of Sheller, P.C. announced today that Shire Pharmaceuticals, LLC has agreed to pay $58.9 million to resolve allegations by the Sheller whistleblower client that Shire violated the False Claims Act. Court documents detailing the civil allegations and settlement were signed by Shire and...

2014-09-24 16:26:15

PHILADELPHIA, September 24, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), today announced that it has reached a final agreement with the U.S. Attorney's Offices for the Eastern District of Pennsylvania and Northern District of Illinois, all 50 states and the District of Columbia to resolve a previously disclosed civil investigation of its sales and marketing practices for a period ending in 2010 relating to ADDERALL XR(R), VYVANSE(R) DAYTRANA(R), LIALDA(R) and...

2014-09-15 08:29:16

PHILADELPHIA, September 15, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED). The FDA is expected to provide a decision in February 2015, based on the...

2014-07-23 08:30:41

Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the...

2014-06-30 04:21:31

DUBLIN, June 30, 2014 /PRNewswire/ -- Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) announces that its Canadian subsidiary(1) has received assessments from the Canadian revenue authorities, entitling it to total cash refunds equivalent to US$410 million(2). Following receipt of the assessments(3), the Company has recorded a net credit to income taxes amounting to US$216 million. This income tax credit will be excluded from Non GAAP income, and will not...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related